List view / Grid view
In 2021 we saw deals move away from the massive megamergers of 2019 to smaller collaboration and partnership agreements. In this article, European Pharmaceutical Review’s Hannah Balfour discusses the key deals of last year, whether the trend of high volume but small value will continue in 2022, and the motivations…
The pharmaceutical industry saw some notable mergers and acquisitions in 2019; this article lists the top 10 by transaction size.
Align Biopharma, an industry technology standards group, introduced 14 leading biopharma companies and technology and service providers as new members.
We caught up with Naghmana Bajwa, MD, Global Medical Affairs Haematology Lead at Shire to find out the latest in haemophilia disease research...
3 April 2017 | By Niamh Marriott, Junior Editor
The National Institute or Health and Care Excellence (NICE) has published final guidance that does not recommend pegylated liposomal irinotecan (Onivyde, Shire).
6 October 2016 | By Niamh Louise Marriott, Digital Content Producer
The Patent Trial and Appeal Board (PTAB) found that the patent was valid in light of the challenges put forward by the petitioner...
20 September 2016 | By Niamh Louise Marriott, Digital Content Producer
CUVITRU is a treatment for patients with primary immunodeficiency (PI), a group of more than 300 genetic disorders in which part of the body's immune system is missing or functions improperly...
8 September 2016 | By Niamh Louise Marriott, Digital Content Producer
The market for attention deficit hyperactivity disorder (ADHD) across the seven major markets (7MM) of the US, France, Germany, Italy, Spain, the UK, and Japan, is set to experience an increase from approximately $6.1 billion in 2014 to $13.9 billion by 2024, at a compound annual growth rate of 8.5%,…
29 July 2016 | By Mandy Parrett, Editorial Assistant
Shire Plc has announced today that the United States Food and Drug Administration (FDA) has granted Fast Track designation for SHP626 (volixibat) for an investigational treatment of adults with nonalcoholic steatohepatitis (NASH) with liver fibrosis.
25 July 2016 | By Niamh Louise Marriott, Digital Content Producer
The positive opinion is based on a pivotal Phase 3 study showing that Onivyde combined with chemotherapy significantly increased overall survival in patients with metastatic pancreatic cancer...
12 July 2016 | By Victoria White, Digital Content Producer
With this approval, Xiidra is the only prescription eye drop indicated for the treatment of both signs and symptoms of this condition...
7 July 2016 | By Victoria White, Digital Content Producer
The EC has granted an extension of the Market Authorisation for Revestive for the treatment of patients aged one year and above with Short Bowel Syndrome...
30 June 2016 | By Victoria White, Digital Content Producer
While the study did not meet its primary endpoint of reducing severity of ROP, it did produce encouraging secondary endpoints related to lung and brain...
14 June 2016 | By Victoria White, Digital Content Producer
PF-00547659 is an investigational biologic being evaluated for the treatment of moderate-to-severe inflammatory bowel disease (IBD)...
3 June 2016 | By Victoria White, Digital Content Producer
Shire and Baxalta have combined businesses, creating a leading global company focused on rare diseases and other highly specialised conditions...
